Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures

Neuro-Oncology

Volumn 14, Issue 12, 2012, Pages 1441-1451

  Eimer, Sandrine ^a   Dugay, Frédéric ^b   Airiau, Kelly ^c   Avril, Tony ^d,e   Quillien, Véronique ^d,e   Belaud Rotureau, Marc Antoine ^b   Belloc, Francis ^c,f  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d Eugene Marquis Center   (France)

^e UNIVERSITÉ DE RENNES 1   (France)

^f HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

cancer stem cells; cyclopamine; epidermal growth factor receptor; glioblastoma; tyrosine kinase inhibitor

Indexed keywords

CD133 ANTIGEN; CYCLOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GLIAL FIBRILLARY ACIDIC PROTEIN; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CELL ADHESION; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG SYNERGISM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASTIC STEM CELLS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VERATRUM ALKALOIDS;

EID: 84869176553     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos266     Document Type: Article

References (51)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. (Pubitemid 47103521)
2. Louis, DN, Ohgaki, H, Wiestler, OD, Cavenee, WK, eds. Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007.
3. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 2010;12:675-684.
4. Nakamura JL. The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications. Expert Opin Ther Targets. 2007;11:463-472. (Pubitemid 46487595)
5. Denysenko T, Gennero L, Roos MA, et al. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. Cell Biochem Funct. 2010;28:343-351.
6. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med. 2006;12:296-300. (Pubitemid 43355075)
7. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8:755-768.
8. Liste I, Garcia-Garcia E, Bueno C, Martinez-Serrano A. Bcl-XL modulates the differentiation of immortalized human neural stem cells. Cell Death Differ. 2007;14:1880-1892. (Pubitemid 350011664)
9. Shiras A, Chettiar ST, Shepal V, Rajendran G, Prasad GR, Shastry P. Spontaneous transformation of human adult nontumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma. Stem Cells. 2007;25:1478-1489. (Pubitemid 47106016)
10. Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem. 2009;284:16705-16709.
11. Aguirre A, Rubio ME, Gallo V. Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. Nature. 2010; 467:323-327.
12. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-760. (Pubitemid 44949604)
13. McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol. 2003;53:1-114. (Pubitemid 137639458)
14. Traiffort E, Angot E, Ruat M. Sonic Hedgehog signaling in the mammalian brain. J Neurochem. 2010;113:576-590.
15. Ehtesham M, Sarangi A, Valadez JG, et al. Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene. 2007;26:5752-5761. (Pubitemid 47312811)
16. Zheng H, Ying H, Wiedemeyer R, et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 2010;17:497-509.
17. Bar EE, Chaudhry A, Lin A, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007;25:2524-2533. (Pubitemid 47582744)
18. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007;17: 165-172. (Pubitemid 46107823)
19. Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med. 2010;17:103-112.
20. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res. 2010;16:3113-3120.
21. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of selfrenewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010;17:362-375.
22. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol. 2008;26:2795-2799.
23. Avril T, Vauleon E, Hamlat A, et al. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and Tcell mediated killing compared to serum-cultured glioblastoma cells. Brain Pathol. 2012;22(2):159-74.
24. Avril T, Saikali S, Vauleon E, et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol. 2010;225:22-33.
25. Coles-Takabe BL, Brain I, Purpura KA, et al. Don't look: growing clonal versus nonclonal neural stem cell colonies. Stem Cells. 2008;26: 2938-2944.
26. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011; 8:486-498.
27. Fan YS, Jayakar P, Zhu H, et al. Detection of pathogenic gene copy number variations in patients with mental retardation by genomewide oligonucleotide array comparative genomic hybridization. Hum Mutat. 2007;28:1124-1132. (Pubitemid 350036917)
28. Witusik-Perkowska M, Rieske P, Hulas-Bigoszewska K, et al. Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies. J Neurooncol. 2010;102:395-407.
29. Bunn PA, Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol. 2002;29:38-44.
30. Eimer S, Belaud-Rotureau MA, Airiau K, et al. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther. 2011;11:1017-1027.
31. Gage FH. Mammalian neural stem cells. Science. 2000;287: 1433-1438. (Pubitemid 30127128)
32. Lois C, Alvarez-Buylla A. Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia. Proc Natl Acad Sci USA. 1993;90:2074-2077. (Pubitemid 23070000)
33. Rietze RL, Valcanis H, Brooker GF, Thomas T, Voss AK, Bartlett PF. Purification of a pluripotent neural stem cell from the adult mouse brain. Nature. 2001;412:736-739. (Pubitemid 32771996)
34. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem. 1981;115:207-216.
35. Geoerger B, Hargrave D, Thomas F, et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13: 109-118.
36. Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS, Stokoe D. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle. 2005;4:1369-1372. (Pubitemid 41437124)
37. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97:880-887. (Pubitemid 41417939)
38. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012-2024. (Pubitemid 41609094)
39. Vogt A, Chuang PT, Hebert J, et al. Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein. J Exp Med. 2004;199:753-761. (Pubitemid 38375195)
40. Ward RJ, Lee L, Graham K, et al. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res. 2009;69: 4682-4690.
41. Thiyagarajan S, Bhatia N, Reagan-Shaw S, et al. Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Res. 2007;67:10642-10646. (Pubitemid 350145887)
42. Mazumdar T, DeVecchio J, Shi T, Jones J, Agyeman A, Houghton JA. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res. 2011;71:1092-1102.
43. Ruiz i Altaba A, Stecca B, Sanchez P. Hedgehog-Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer. Cancer Lett. 2004;204:145-157. (Pubitemid 38167718)
44. Ecke I, Petry F, Rosenberger A, et al. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009; 69:887-895.
45. Vorechovsky I, Benediktsson KP, Toftgard R. The patched/hedgehog/ smoothened signalling pathway in human breast cancer: no evidence for H133Y SHH, PTCH and SMO mutations. Eur J Cancer. 1999; 35:711-713. (Pubitemid 29258138)
46. Mueller MT, Hermann PC, Witthauer J, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009;137:1102-1113.
47. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009; 361:1164-1172.
48. Uchida H, Arita K, Yunoue S, et al. Role of sonic hedgehog signaling in migration of cell lines established from CD133-positive malignant glioma cells. J Neurooncol. 2011;104(3):697-704.
49. Zhang X, Harrington N, Moraes RC, Wu MF, Hilsenbeck SG, Lewis MT. Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat. 2009;115:505-521.
50. Meyers-Needham M, Lewis JA, Gencer S, et al. Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. Mol Cancer Ther. 2012;11:1092-1102.
51. Mimeault M, Moore E, Moniaux N, et al. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer. 2006;118:1022-1031. (Pubitemid 43157681)